Head-To-Head Survey: Sanara MedTech (NASDAQ:SMTI) & ReWalk Robotics (NASDAQ:LFWD)

ReWalk Robotics (NASDAQ:LFWDGet Free Report) and Sanara MedTech (NASDAQ:SMTIGet Free Report) are both small-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation and Earnings

This table compares ReWalk Robotics and Sanara MedTech”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ReWalk Robotics $13.85 million 1.03 -$22.13 million ($2.49) -0.65
Sanara MedTech $64.99 million 4.57 -$4.30 million ($0.99) -34.34

Sanara MedTech has higher revenue and earnings than ReWalk Robotics. Sanara MedTech is trading at a lower price-to-earnings ratio than ReWalk Robotics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

ReWalk Robotics has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ReWalk Robotics and Sanara MedTech, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ReWalk Robotics 0 0 1 1 3.50
Sanara MedTech 0 0 2 0 3.00

ReWalk Robotics presently has a consensus price target of $13.00, indicating a potential upside of 702.47%. Sanara MedTech has a consensus price target of $47.00, indicating a potential upside of 38.24%. Given ReWalk Robotics’ stronger consensus rating and higher possible upside, equities analysts clearly believe ReWalk Robotics is more favorable than Sanara MedTech.

Insider & Institutional Ownership

26.8% of ReWalk Robotics shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 2.5% of ReWalk Robotics shares are held by company insiders. Comparatively, 54.1% of Sanara MedTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares ReWalk Robotics and Sanara MedTech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ReWalk Robotics -77.21% -43.02% -31.53%
Sanara MedTech -10.71% -19.86% -10.91%

Summary

Sanara MedTech beats ReWalk Robotics on 9 of the 14 factors compared between the two stocks.

About ReWalk Robotics

(Get Free Report)

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

About Sanara MedTech

(Get Free Report)

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.